Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04925375 · ClinicalTrials.gov registry record · Phase 2

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

A Phase 2 study of Interstitial Lung Disease and Common Variable Immunodeficiency, sponsored by Children's Hospital Medical Center, Cincinnati.

Recruiting
Registry status
Phase 2
Development phase
38
Enrollment target
6
Study locations

NCT04925375 is a Phase 2 study of Interstitial Lung Disease and Common Variable Immunodeficiency that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 38 participants, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04925375, a Phase 2 study of Interstitial Lung Disease and Common Variable Immunodeficiency, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.

RECRUITING
Registry status
Phase 2
Development phase
38 participants
Enrollment target
6
Study locations

Study Summary

There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Funding Source - FDA OOPD

Conditions Studied

Interstitial Lung Disease Common Variable Immunodeficiency

Interventions

  • OTHER Placebo
  • DRUG Abatacept

Study Locations (6)

California

  • University of California, San Francisco - San Francisco

Florida

  • University of South Florida - Tampa

Massachusetts

  • Lahey Hospital and Medical Center - Burlington

Minnesota

  • Mayo Clinic - Rochester

North Carolina

  • Duke University Health System - Durham

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2021-07-14
Est. Completion 2026-07
Phase Phase 2

Sponsor

Children's Hospital Medical Center, Cincinnati

571 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04925375

The ClinicalTrials.gov registry entry for NCT04925375 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (93% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Interstitial Lung Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04925375 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04925375 about?

NCT04925375 is a clinical study titled "Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease". There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomize...

What is the current status of trial NCT04925375?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2021-07-14. Estimated completion is 2026-07.

What conditions does trial NCT04925375 study?

This clinical trial studies the following conditions: Interstitial Lung Disease, Common Variable Immunodeficiency.

What interventions are being tested in trial NCT04925375?

The interventions under investigation include: Placebo (OTHER), Abatacept (DRUG).

Who is sponsoring clinical trial NCT04925375?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04925375 being conducted?

This trial has 6 study locations across California, Florida, Massachusetts, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Interstitial Lung Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Interstitial Lung Disease

All registered trials for this condition

Common Variable Immunodeficiency

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.